The chemotherapeutic efficacy of cefpirome (HR 810), a new polar aminothiazolylcephalosporin and that of ceftazidime, cefotaxime, cefoperazone, latamoxef and cefodizime were examined against experimental pneumonia caused by Klebsiella pneammlliae DT-S in mice. When compared in terms of MIC values against the infecting organism and the pharmacokinetic pattern, cefpirome showed equal activity and a similar pharmacokinetic behavior to ceftazidime and cefotaxime in mice. Trials to assess the bactericidial activity in vhro, however, showed that cefpirome displayed a more marked bactericidal effect in pneumonic mice than the other cephalosporins tested. Only cefodizime, a cephalosporin with extremely high and prolonged blood and tissue levels in experimental animals exerted chemotherapeutic effects similar to cefpirome. After cefpirome or cefodizime medication (50 mg/kg), the viable counts in the lungs of experimental animals fell steadily to 1/10,000 of the pretreatment level and, in contrast to the reference compounds, no regrowth of the challenge organisms could be observed with both drugs. Moreover, with ED.-,,,,s ranging from 1.1 to 59.1 mg/kg in treatment studies, cefpirome as well as cefodizime were two to ten times more effective than ceftazidime and cefotaxime, whereas cefoperazone and latamoxef were considerably less effective.
Cefpirome
(3-((2,3-cyclopenteno-I-pyridium)methyl)-7-(2-syn-methoximino-2-(2-aminothiazol-4-yl)acetamido)ceph-3-em-4-carboxylate, HR 810) is a new semi-synthetic parenteral cephalosporin antibiotic with a broad spectrum of antibacterial activity in vitro and in rivo. The cefpirome spectrum includes Enterobacteriaceae, strains of the genera Pseudonaonas and Staphylococcus as well as streptococci of the sero-group D1~4). It is also highly effective in controlling systemic and localized infections caused by these strains in experimental animals5). Investigations on the pharmacokinetic behavior of cefpirome showed high and sustained blood levels and good diffusibility into various tissues of experimental animals after sc, iv and im injections6) . The purpose of this study was to determine the chemotherapeutic efficacy of cefpirome in experimentally induced lung infections in mice as compared with that of ceftazidime, cefotaxime, cefoperazone, latamoxef and cefodizime. At the same time the concentrations of these drugs in the blood and lungs of infected mice were also determined.
The infecting organism used in these studies was Klebsiella pnewnoniae DT-S, a strain which caused acute pulmonary infection in mice 7-10).
Materials and Methods
Antibiotics Cefpirome (HR 810, sulfate), cefotaxime and cefodizime (HR 221) were prepared by Hoechst AG, Frankfurt, FRG; ceftazidime, cefoperazone and latamoxef were obtained from a commercial source.
Challenge Organism
The infecting organism, K. pneumoniae DT-S, was kindly provided by Takeda Chemical Industries, Ltd., Osaka, Japan. The strain was maintained by intrabronchial passage in mice every 14 days and stored at room temp on Mueller-Hinton agar. For the in vivo experiments, the strain was transferred to brain heart infusion agar slants and, after incubation at 37CC for 20 hours, the bacteria were cultured in brain heart infusion broth for 16 hours at 37C. This culture, containing approximately 5 x 108 colony forming units/ml (cfu/ml), was then used for the infection studies.
The minimum inhibitory concentrations (MICs), defined as the lowest concentrations of the antibiotics that suppressed visible growth after 20 hours incubation at 37°C of an inoculum of 5 x 105 cfu/ml K. pnenmoniae DT-S, were determined in Mueller-Hinton broth (Difco) as previously described1,2,5).
Production of Pneumonia; Infection Procedure Experimental pneumonia was produced as previously described by NISHI and TSUCHIYA7,8 ). In brief, up to 120 male NMRI mice, strain NMKf Hoe SPF 71, were placed in an exposure chamber. Four ml of the Klebsiella suspension were put in a nebulizer (Vaponefrin Pocket Nebulizer, USV Pharmaceutical Co., U.S.A.) and nebulized with compressed air at a pressure of one kg/cm2 for 40 minutes. Half an hour after infection, up to 2.5 x, 102 cfu/g tissue of K. pneumoniae DT-S were found in the lungs of the exposed mice.
Bactericidal Effect In Vitro (Time-kill Curves) The bactericidal effect of the cephalosporin antibiotics on K. pneumoniae DT-S in vitro was assessed by killing curve experiments. 18-hours-cultures of K. pneuanoniae DT-S were suspended in 1 liter of Mueller-Hinton broth at a density of about 105 bacteria per ml and incubated on a shaker for 24 hours at 37°C. After two hours, cephalosporins were added in concentrations of approximately equal to the MIC. Samples were removed after 0, 1, 2, 4, 6 and 24 hours of incubation; they were diluted immediately with Mueller-Hinton broth and plated on drug-free Mueller-Hinton agar to determine the cfu.
Klebsiella pneuntoniae Time-Kill Curves In Vivo Mice with experimentally induced pneumonia were injected with a 50 mg/kg dose of the test antibiotics 18 hours after infection. They were killed prior to and at intervals between 1 and 48 hours after the administration of antibiotic (ten animals/time point for each group). 0.1 ml of blood was taken from the inferior vena cava, plated on Mueller-Hinton agar and incubated for colony counts. The lungs were excised, weighed, diluted in nine times the weight of 10 mm phosphate buffered saline (PBS), homogenized, serially diluted and plated. The cfu were counted after 24 hours incubation at 37°C. Analysis of variance was used for statistical comparisons.
Treatment of Pulmonary Infections
Mice were infected by the aerosol method and the pneumonia was allowed to become well established before treatment was carried out. The antibiotics were injected subcutaneously in serial two-fold dose concentrations as follows; once 18 hours or 28 hours after infection, twice 21 and 28 hours after infection or three times, 18, 19 and 20 hours after infection. The volume administered was 1 ml/mouse. Ten control mice were left untreated. The number of dead mice was recorded daily. On the tenth day after infection, the surviving animals were sacrificed and the lungs removed for the determination of bacterial recovery. The lungs were homogenized with nine times the weight of 10 mm PBS in an Ultra Turrax homogenizer (Janke & Kunkel KG, FRG). Ten-fold serial dilutions of the homogenate in PBS were prepared, and 0.1 ml of the samples was plated on Mueller-Hinton agar plates (Difco). The agar plates were incubated at 37°C for 20 hours and the cfu/g tissue counted. The median effective dose (ED50, mg/kg/dose), i.e. the amount of antibiotic required for the survival of 50% of the animals, and the median clearance dose (CD50, mg/kg/dose), i.e. the amount of antibiotic required for eradication of K. pneumoniae from the lungs of 50% of the infected animals, were calculated by probit analysis.
Bioassay
The levels of the cephalosporins in murine blood and lung tissue at various intervals after a single subcutaneous injection of 50 mg/kg were determined by agar diffusion technique6, 10, 11) Each agent was present at once the MIC: Cefpirome, 0.03 pg/ml; ceftazidirne, 0.06 l!g/ml; cefotaxime, 0.015 pg/ml; cefoperazone, 0.06 ug/ml and latamoxef, 0.25 pg/lm . Arrow, addition of the drugs.
-Control, 0 cefpirome, 0 ceftazidime, • cefotaxime, A cefoperazone, 0 latamoxef , c cefodizime.
Time of incubation (hours) Results
Bactericidal Activity In Vitro
A comparison of the bactericidal activity of cefpirome and other cephalosporin antibiotics against K. pneumoniae DT-S is shown in Fig. 1 . Each drug was present in concentrations approximate to the MIC. In the first six hours of incubation, cefpirome and cefodizime at 0.03 pg/ml were as effective as the other cephalosporins at concentrations of: 0.015 leg/ml (cefotaxime), 0.06 pg/ml (ceftazidime and cefoperazone) and 0.25 pg/ml (latamoxef). But then, a rapid regrowth of K. pneumoniae DT-S was observed with four out of five reference compounds, which was not true for cefpirome and cefodizime. Only few bacteria were found after cefodizime incubation, but no viable counts could be detected after 24 hours of cefpirome incubation.
Bactericidal Activity in Pneumonic Mice
In the clearance studies, single sc doses of the cephalosporins (50 mg/kg) were administered 18 hours after challenge when approximately 9 x 105 cfu/g of K. pneumoniae DT-S in the lungs of the mice were present. During the first eight hours after medication, cefpirome, cefotaxime, ceftazidime and cefo- dizime all displayed similar killing capacity and caused a mean reduction in the viable cell count in the lungs of 2.4-2.7 log cfu/g (Table I and Fig. 2) . With cefpirome and, to a smaller extent, also with cefodizime, a further reduction in challenge organisms by up to 1/10,000 of the pretreatment level was Not determined. Initial bacterial titer (18 hours after exposure) was 5.82 log cfu/g lung.
Values are significantly different from those of cefpirome (P<0.05). ** Hours after treatment . observed and in eight out of ten and five out of ten animals, respectively, no bacteria could be found in the lungs at 48 hours. Bacteremia did not occur in any of the test animals in each group. With ceftazidime and, in particular, with cefotaxime, a rapid regrowth could be observed at 24 and 48 hours (Fig. 2) , and bacteria were eradicated from the lungs of only two of the ten mice in the ceftazidime group and from none in the cefotaxime group. Moreover bacterial blood titers at 48 hours were detected in eight out of ten mice in each group. Despite their good antibacterial activity in vitro and despite the high latamoxef-levels in the infected lungs (Table 4) , latamoxef as well as cefoperazone, exhibited only a slight bactericidal effect in vivo, and the bacterial growth rate in treated mice was similar to that seen in the controls. At 48 hours after cefoperazone or latamoxef treatment, high bacterial counts were determined not only in the lungs but also in the blood of nearly all the mice. (Tables 2 and 3 ). /g, respectively) . The lung level of cefoperazone was below the limit of detection (0.8 ug/ml) before 1 hour after injection. 
